Meeting
2019 ASCO Annual Meeting
Efficacy and safety of apatinib in extensive stage small cell lung cancer patients failed from two or more lines of chemotherapy.
Authors
Yutao Liu
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Yutao Liu , Xingsheng Hu , Jiang Jun , Lin Yang , Shengyu Zhou , Peng Liu , Junling Li , Yan Wang , Xuezhi Hao , Yuankai Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02995187
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8553)
DOI
10.1200/JCO.2019.37.15_suppl.8553
Abstract #
8553
Poster Bd #
309
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Apatinib for patients (pts) with advanced soft tissue sarcoma (STS) after chemotherapy: A prospective, open-label, single-arm, multicentered study.
First Author: Haiyan Hu
Poster
2023 ASCO Annual Meeting
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.
First Author: Yan Huang
Poster
2022 ASCO Annual Meeting
Preliminary safety and efficacy of camrelizumab plus nab-paclitaxel and carboplatin as frontline setting in extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Shengxiang Ren
